Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance

被引：0
作者：
Susan Cleator
Anna Tsimelzon
Alan Ashworth
Mitch Dowsett
Timothy Dexter
Trevor Powles
Susan Hilsenbeck
Helen Wong
C. Kent Osborne
Peter O’Connell
Jenny C. Chang
机构：
[1] The Institute of Cancer Research,Breakthrough Breast Cancer Research Centre
[2] Baylor College of Medicine,Breast Center and the Departments of Medicine, and Molecular and Cellular Biology
[3] and The Methodist Hospital,undefined
[4] The Royal Marsden Hospital,undefined
[5] Virginia Commonwealth University Medical Center,undefined
来源：
Breast Cancer Research and Treatment | 2006年 / 95卷
关键词：
AC chemotheraphy; breast cancer; predictive markers; Taxotere;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：229 / 233
页数：4
相关论文
共 21 条
  • [1] Fisher B(1998)Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1451-1467
  • [2] Mamounas EP(1998)Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930-942
  • [3] Fisher B(1998)Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer J Clin Oncol 13 537-540
  • [4] Bryant J(1998)Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672-2685
  • [5] Wolmark N(1999)Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer J Clin Oncol 17 3058-3063
  • [6] Chang J(2003)Gene expression profiling predicts therapeutic response to docetaxel (Taxotere(tm)) in breast cancer patients Lancet 362 280-287
  • [7] Powles TJ(2001)Analyzing high-density oligonucleotide gene expression array data J Cell Biochem 80 192-202
  • [8] Allred DC(2002)A paradigm for class prediction using gene expression profiles J Comput Biol 9 505-511
  • [9] Chang JC(1997)Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel Oncology 11 37-40
  • [10] Wooten EC(2004)Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J Clin Oncol 22 2284-2293
123